Company / Financials
Aclaris Therapeutics, Inc. Financials
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$7.8M
FY2025 · -75.0% YoY
Net Income
-$64.9M
FY2025 · +26.6% YoY
Profit Margin
-829.6%
FY2025 · net income / revenue
ROE
-63.0%
FY2025 · return on equity
Total Assets
$160.5M
FY2025
Total Debt
-
FY2025
Equity
$103.1M
FY2025
ROA
-40.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$7.8M-75.0% YoYNet Income HistoryProfit after all expenses and taxes-$64.9M+26.6% YoYGross Profit HistoryRevenue minus cost of goods sold$3.2MCost of Revenue HistoryDirect costs of producing goods and services sold$2.1M-38.9% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$76.4M+21.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$22.0M-32.2% YoYR&D Expense HistoryResearch and development spending$52.6M-46.5% YoYIncome Tax HistoryTotal income tax expense-$367.0K0.0% YoYEPS (Basic) HistoryBasic earnings per share-$1.71-34.6% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.71-34.6% YoY